drugset / Trial / NCT00857467
Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.
RandomizedCrossoverTriple-blindTreatment
Summary
This is a healthy volunteer three-way crossover study. A total of 12 subjects will receive three single administrations of 1 g rectal suppositories (containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), with a washout period of at least 7 days between dosings. A further 12 subjects will receive three single administrations of 2 g rectal suppositories (containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), again with a 7 day washout period between dosings. The pharmacodynamic response, pharmacokinetics and safety profile will be determined.
Timeline
- Start
- 2009-02
- Primary completion
- 2009-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NRL001 | Small molecule | 5 mg | Other |
| Subject | NRL001 | Small molecule | 10 mg | Other |
| Subject | NRL001 | Small molecule | 15 mg | Other |
Indications
No indication recorded.